An exciting application for this hypothesis was confirmed by Horiuchi et al.31, which indicates that aggressive breast tumors with elevated c-myc expression were uniquely sensitive to the CDK1/2 inhibitors. The gene discussed is MYC; the disease is breast neoplasm.